

# Redx Pharma Plc

07:52 29 Oct 2018

## Redx Pharma chief elected to industry body role

Redx Pharma Plc (LON:REDX) has confirmed its chief executive, Lisa Anson, has been elected to senior industry role.

From the start of 2019, she will serve as a director of the UK BioIndustry Association for a three-year term.

READ: Redx Pharma to focus on progressing oncology and fibrotic drugs in 2019

"I am delighted to be elected to join the BIA Board," said Anson.

"I am passionate about the UK Biotech sector, as it is not only the focus for much of the exciting science in the UK, but it is also an important sector supporting the UK economy.

"Having previously been president of the Association of the British Pharmaceutical Industry (ABPI), I am personally excited at the prospect of working with the BIA to further the industry."

**Price:** 5.25p

**Market Cap:** £6.64M

### 1 Year Share Price Graph



### Share Information

**Code:** REDX

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	14.88p	4.75p

**Sector:** Pharma & Biotech

**Website:** RedxPharma.com

### Company Synopsis:

Redx Pharma was formed in 2010 and is an established drug discovery and development company based at Alderley Park. The Group's work has been endorsed by partnerships with global pharmaceutical companies, and focuses on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need in cancer and fibrosis.

### Author:

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

**action@proactiveinvestors.com**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content

published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.